Published online Aug 21, 2019. doi: 10.5527/wjn.v8.i4.75
Peer-review started: March 4, 2019
First decision: April 11, 2019
Revised: July 9, 2019
Accepted: July 16, 2019
Article in press: July 16, 2019
Published online: August 21, 2019
Core tip: Antineutrophil cytoplasmic antibody-associated vasculitis is characterized by a remitting - relapsing course of disease that requires long term immunosuppression. Mycophenolic acid has been evaluated as induction and remission maintenance agent in the treatment of antibody-associated vasculitis as a less toxic agent compared to cyclophosphamide and azathioprine. Mycophenolate has been proven a potent immunosuppressive agent and non-inferior to other available drugs with comparable side effect profile, but several studies have shown a higher relapse rate following discontinuation of mycophenolate or in mycophenolate treated subjects. In this review, the role of mycophenolate in treatment of antibody-associated vasculitis is further discussed.